Article
Better Responses Observed With Selpercatinib Versus Prior Systemic Therapies for RET+ NSCLC
Rating:
0.0
Views:
112
Likes:
1
Library:
1
Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with non–small cell lung cancer whose tumors harbor RET fusions.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value